OraSure Files Routine 8-K; No New Material Info

TL;DR

**OraSure filed a standard 8-K, nothing new to see here.**

AI Summary

OraSure Technologies, Inc. filed an 8-K on January 4, 2024, to report a 'Regulation FD Disclosure' and 'Other Events.' This filing is primarily administrative, confirming the company's basic information like its Delaware incorporation and its common stock trading on The Nasdaq Stock Market LLC under the symbol OSUR. For investors, this filing is a routine update and doesn't contain new financial or operational news, meaning there's no immediate impact on the stock price from this specific document.

Why It Matters

This filing is largely administrative, confirming basic company details and compliance, and does not contain new financial or operational information that would typically move the stock.

Risk Assessment

Risk Level: low — This 8-K is a routine administrative filing and does not introduce any new financial or operational risks.

Analyst Insight

Investors should view this 8-K as a standard compliance filing that provides no new material information to act upon; focus on future filings for operational or financial updates.

Key Numbers

• 001-16537 — Commission File Number (OraSure Technologies, Inc.'s SEC file number)
• 36-4370966 — I.R.S. Employer Identification No. (OraSure Technologies, Inc.'s IRS number)
• $0.000001 — par value per share (par value of OraSure's Common Stock)

Key Players & Entities

• OraSure Technologies, Inc. (company) — the registrant filing the 8-K
• Delaware (company) — state of incorporation for OraSure Technologies, Inc.
• The Nasdaq Stock Market LLC (company) — exchange where OraSure's common stock is registered
• OSUR (company) — trading symbol for OraSure Technologies, Inc.
• January 4, 2024 (date) — date of earliest event reported and filing date

FAQ

Key Financial Figures

• $0.000001 — ange on which registered Common Stock, $0.000001 par value per share OSUR The Nasdaq Sto

Filing Documents

• osur-20240104.htm (8-K) — 35KB
• exhibit991_sapphireinves.htm (EX-99.1) — 18KB
• exhibit992_projectsapphire.htm (EX-99.2) — 21KB
• exhibit991_sapphireinves001.jpg (GRAPHIC) — 78KB
• exhibit991_sapphireinves002.jpg (GRAPHIC) — 291KB
• exhibit991_sapphireinves003.jpg (GRAPHIC) — 148KB
• exhibit991_sapphireinves004.jpg (GRAPHIC) — 121KB
• exhibit991_sapphireinves005.jpg (GRAPHIC) — 90KB
• exhibit991_sapphireinves006.jpg (GRAPHIC) — 84KB
• exhibit991_sapphireinves007.jpg (GRAPHIC) — 111KB
• exhibit991_sapphireinves008.jpg (GRAPHIC) — 107KB
• exhibit991_sapphireinves009.jpg (GRAPHIC) — 104KB
• exhibit991_sapphireinves010.jpg (GRAPHIC) — 125KB
• exhibit991_sapphireinves011.jpg (GRAPHIC) — 125KB
• exhibit991_sapphireinves012.jpg (GRAPHIC) — 145KB
• image_0.jpg (GRAPHIC) — 12KB
• 0001116463-24-000003.txt ( ) — 2335KB
• osur-20240104.xsd (EX-101.SCH) — 2KB
• osur-20240104_lab.xml (EX-101.LAB) — 23KB
• osur-20240104_pre.xml (EX-101.PRE) — 12KB
• osur-20240104_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

ITEM 7.01 Regulation FD Disclosure. OraSure Technologies, Inc. (the "Company") hereby furnishes the Investor Presentation that the Company will present to analysts and investors on or after the date hereof, which is attached as Exhibit 99.1 to this Current Report on Form 8-K ("Current Report"), is incorporated herein by reference and will be available on the Company's website at www.orasure.com. The information in this Item and attached Exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall such information and Exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such a filing. The fact that the information and Exhibit are being furnished should not be deemed an admission as to the materiality of any information contained therein. The Company undertakes no duty or obligation to publicly update or revise the information contained in this Current Report or attached Exhibit.

01 Other Events

ITEM 8.01 Other Events On January 4, 2024, the Company issued a press release announcing the Company's investment in KKR Sapphiros, L.P. ("Sapphiros") and the Company's entry into a wide-ranging distribution relationship with Sapphiros and certain of its related entities. A copy of the press release is attached as Exhibit 99.2 to this Current Report and is incorporated herein by reference.

Forward Looking Statements

Forward Looking Statements This Current Report contains certain "forward-looking statements" within the meaning of the Federal securities laws, including with respect to products, product development and manufacturing activities, the investment of the Company in, and distribution relationship with Sapphiros and certain of its related entities, revenue growth, cash flow, increasing margins and other matters. Words such as "expects," "estimates," "forecasts," "intends," "plans," "projects," "could," "may," "should," "will" or other similar words and expressions are intended to identify these forward-looking statements. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: Sapphiros' and its related entities' ability to seek and obtain regulatory approval for products in development; the Company's ability to satisfy customer demand; ability to reduce the Company's spending rate, capitalize on manufacturing efficiencies and drive profitable growth; ability to achieve the anticipated cost savings as a result of the Company's business restructuring; ability to market and sell products, whether through the Company's internal, direct sales force or third parties; impact of significant customer concentration in the genomics business; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for the Company's products; ability to manufacture or have manufactured products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effective

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Investor Presentation. 99.2 Press Release, dated January 4, 2024, announcing OraSure Technologies, Inc.'s investment in and strategic relationship with KKR Sapphiros, L.P. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORASURE TECHNOLOGIES, INC. Date: January 4, 2024 By: /s/ Carrie Eglinton Manner Carrie Eglinton Manner President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR